StockNews.com initiated coverage on shares of Minerva Neurosciences (NASDAQ:NERV – Free Report) in a research note released on Tuesday morning. The firm issued a sell rating on the biopharmaceutical company’s stock.
Separately, HC Wainwright dropped their price objective on shares of Minerva Neurosciences from $11.00 to $7.00 and set a neutral rating on the stock in a research note on Thursday, May 2nd.
Get Our Latest Analysis on NERV
Minerva Neurosciences Stock Down 2.7 %
Minerva Neurosciences (NASDAQ:NERV – Get Free Report) last released its quarterly earnings data on Tuesday, August 6th. The biopharmaceutical company reported ($1.09) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.97) by ($0.12). As a group, equities analysts predict that Minerva Neurosciences will post -1.89 earnings per share for the current year.
About Minerva Neurosciences
Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders.
Further Reading
- Five stocks we like better than Minerva Neurosciences
- How to Find Undervalued Stocks
- MarketBeat Week in Review – 8/5 – 8/9
- Basic Materials Stocks Investing
- Cassava Sciences: A Hot Stock to Trade, Invest, or Avoid?
- How to Invest in the Best Canadian Stocks
- The Cannabis Sector: Profitability Takes Center Stage
Receive News & Ratings for Minerva Neurosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Minerva Neurosciences and related companies with MarketBeat.com's FREE daily email newsletter.